Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
Emma
E
Hudson
Diana
D
Westmoreland
Christopher
C
Gorman
Christopher H
CH
Poynton
Jason F
JF
Lester
Timothy S
TS
Maughan
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000276:immunology; D008875:Middle Aged; D000069283:Rituximab; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014740:Vidarabine; C024352:fludarabine